The relationship between bipolar disorder and type 2 diabetes: More than just co-morbid disorders

Annals of Medicine

Volumn 45, Issue 2, 2013, Pages 171-181

  Calkin, Cynthia V ^a   Gardner, David M ^a   Ransom, Thomas ^a   Alda, Martin ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Bipolar disorder; Co morbidity; Diabetes; Epigenetics; Etiology; Mortality; Pathophysiology; Pharmacotherapy; Treatment

Indexed keywords

ARIPIPRAZOLE; BAG 1 PROTEIN; C REACTIVE PROTEIN; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CORTICOTROPIN RELEASING FACTOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOCORTICOID; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

ADVERSE OUTCOME; ATHEROSCLEROTIC PLAQUE; BIPOLAR DISORDER; BLOOD GLUCOSE MONITORING; BODY MASS; BODY WEIGHT; BRAIN SIZE; CARBOHYDRATE INTAKE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHILD ABUSE; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; COMORBIDITY; DIABETIC PATIENT; DIET THERAPY; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA METHYLATION; DOWN REGULATION; ENERGY EXPENDITURE; ENZYME INHIBITION; EXERCISE; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HAMILTON SCALE; HEALTH CARE DISPARITY; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIPPOCAMPUS; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HOSPITALIZATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERPHAGIA; HYPERSOMNIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LIFE STRESS; MAJOR DEPRESSION; MEDICAL CARE; META ANALYSIS (TOPIC); METABOLIC DISORDER; METABOLIC SYNDROME X; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATIENT CARE; PATIENT COMPLIANCE; PHOSPHOLIPID METABOLISM; PREVALENCE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SEDENTARY LIFESTYLE; SELF CARE; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN;

BIPOLAR DISORDER; DIABETES MELLITUS, TYPE 2; HUMANS; RISK FACTORS;

EID: 84873400499     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.687835     Document Type: Review

References (130)

1. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. JAffect Disord. 2003;73:123-31.
2. Judd LL, Schettler PJ, Solomon DA, Maser JD, Coryell W, Endicott J, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. JAffect Disord. 2008;108:49-58.
3. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-50.
4. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: fi ndings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7:424-30.
5. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. JAffect Disord. 2002;70:19-26.
6. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156:1417-20.
7. Lilliker SL. Prevalence of diabetes in a manic-depressive population. Compr Psychiatry. 1980;21:270-5.
8. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005;17:83-93.
9. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. JClin Psychiatry. 2006;67 Suppl 9:25-30.
10. Kilbourne AM, Post EP, Nossek A, Drill L, Cooley S, Bauer MS. Improving medical and psychiatric outcomes among individuals with bipolar disorder: a randomized controlled trial. Psychiatr Serv. 2008; 59:760-8.
11. Fagiolini A, Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. JClin Psychiatry. 2009;70 Suppl 3:22-9.
12. Sullivan G, Han X, Moore S, Kotrla K. Disparities in hospitalization for diabetes among persons with and without co-occurring mental disorders. Psychiatr Serv. 2006;57:1126-31.
13. Yehuda R. Stress and glucocorticoid. Science. 1997;275:1662-3.
14. Cervantes P, Gelber S, Kin FN, Nair VN, Schwartz G. Circadian secretion of cortisol in bipolar disorder. JPsychiatry Neurosci. 2001; 26:411-6.
15. Rybakowski JK, Twardowska K. The dexamethasone/corticotropinreleasing hormone test in depression in bipolar and unipolar affective illness. JPsychiatr Res. 1999;33:363-70.
16. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamicpituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry. 2004;184:496-502.
17. Holsboer F, Lauer CJ, Schreiber W, Krieg JC. Altered hypothalamicpituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology. 1995;62:340-7.
18. Fitzgerald PJ. Is elevated noradrenaline an aetiological factor in a number of diseases? Auton Autacoid Pharmacol. 2009;29:143-56.
19. Brindley DN, Rolland Y. Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis. Clin Sci (Lond). 1989;77:453-61.
20. Holmang A, Bjorntorp P. The effects of cortisol on insulin sensitivity in muscle. Acta Physiol Scand. 1992;144:425-31.
21. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000;2(3 Pt 1):180-90.
22. Szendroedi J, Schmid AI, Chmelik M, Toth C, Brehm A, Krssak M, et al. Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med. 2007;4:e154.
23. Kato T. The role of mitochondrial dysfunction in bipolar disorder. Drug News Perspect. 2006;19:597-602.
24. Johannsen DL, Ravussin E. The role of mitochondria in health and disease. Curr Opin Pharmacol. 2009;9:780-6.
25. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002;51: 2944-50.
26. Maurer IC, Schippel P, Volz HP. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 2009;11:515-22.
27. Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, et al. The antiapoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci. 2005;25:4493-502.
28. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 2001;65: 391-426.
29. Lovestone S, Killick R, Di Forti M, Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 2007;30:142-9.
30. Yang SD, Yu JS, Lee TT, Yang CC, Ni MH, Yang YY. Dysfunction of protein kinase FA/GSK-3 alpha in lymphocytes of patients with schizophrenic disorder. JCell Biochem. 1995;59:108-16.
31. Rowe MK, Wiest C, Chuang DM. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev. 2007;31:920-31.
32. Horrobin DF, Bennett CN. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids. 1999;60:217-34.
33. Torkamani A, Topol EJ, Schork NJ. Pathway analysis of seven common diseases assessed by genome-wide association. Genomics. 2008;92: 265-72.
34. Ban HJ, Kim SC, Seo J, Kang HB, Choi JK. Genetic and metabolic characterization of insomnia. PLoS One. 2011;6:e18455.
35. Bifulco A, Moran PM, Baines R, Bunn A, Stanford K. Exploring psychological abuse in childhood: II. Association with other abuse and adult clinical depression. Bull Menninger Clin. 2002;66:241-58.
36. Fish EW, Shahrokh D, Bagot R, Caldji C, Bredy T, Szyf M, et al. Epigenetic programming of stress responses through variations in maternal care. Ann N Y Acad Sci. 2004;1036:167-80.
37. Heim C, NemeroffCB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry. 2001;49:1023-39.
38. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7:847-54.
39. Penza KM, Heim C, NemeroffCB. Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. Arch Womens Ment Health. 2003;6:15-22.
40. Alvarez MJ, Roura P, Oses A, Foguet Q, Sola J, Arrufat FX. Prevalence and clinical impact of childhood trauma in patients with severe mental disorders. JNerv Ment Dis. 2011;199:156-61.
41. Garno JL, Goldberg JF, Ramirez PM, Ritzler BA. Impact of childhood abuse on the clinical course of bipolar disorder. Br J Psychiatry. 2005;186:121-5.
42. Centers for Disease Control and Prevention (CDC). Adverse childhood experiences reported by adults-fi ve states, 2009. MMWR Morb Mortal Wkly Rep. 2010;59:1609-13.
43. Hammersley P, Dias A, Todd G, Bowen-Jones K, Reilly B, Bentall RP. Childhood trauma and hallucinations in bipolar affective disorder: preliminary investigation. Br J Psychiatry. 2003;182:543-7.
44. Goodwin RD, Weisberg SP. Childhood abuse and diabetes in the community. Diabetes Care. 2002;25:801-2.
45. Danese A, Moffitt TE, Harrington H, Milne BJ, Polanczyk G, Pariante CM, et al. Adverse childhood experiences and adult risk factors for age-related disease: depression, infl ammation, and clustering of metabolic risk markers. Arch Pediatr Adolesc Med. 2009;163: 1135-43.
46. Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A. Elevated infl ammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry. 2008;65:409-15.
47. Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. Childhood maltreatment predicts adult infl ammation in a life-course study. Proc Natl Acad Sci USA. 2007;104:1319-24.
48. Danese A, Caspi A, Williams B, Ambler A, Sugden K, Mika J, et a l. Biological embedding of stress through infl ammation processes in childhood. Mol Psychiatry. 2011;16:244-6.
49. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51: 245-70.
50. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy VA, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. JAffect Disord. 2009;116:214-7.
51. Cunha AB, Andreazza AC, Gomes FA, Frey BN, da Silveira LE, Goncalves CA, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258:300-4.
52. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127-37.
53. Calkin C, van de Velde C, Ruzickova M, Slaney C, Garnham J, Hajek T, et al. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord. 2009;11:650-6.
54. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. JClin Psychiatry. 2001;62:486-91.
55. Sylvia LG, Dupuy JM, Ostacher MJ, Cowperthwait CM, Hay AC, Sachs GS, et al. Sleep disturbance in euthymic bipolar patients. J Psychopharmacol. 2011 Sep 29 [Epub ahead of print].
56. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010;33:414-20.
57. Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management]. Encephale. 2005;31(4 Pt 1):507-16.
58. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44: 778-83.
59. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry. 2006;14:152-64.
60. Gunes A, Melkersson KI, Scordo MG, Dahl ML. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. JClin Psychopharmacol. 2009;29:65-8.
61. Melkersson KI, Gunes A, Dahl ML. Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine-and olanzapinetreated patients. Hum Psychopharmacol. 2010;25:347-52.
62. Herken H, Erdal M, Aydin N, Sengul C, Karadag F, Barlas O, et a l. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol. 2009;28:515-9.
63. Ardizzone TD, Bradley RJ, Freeman AM III, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 2001;923:82-90.
64. Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23: 69-80.
65. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999;40:438-43.
66. Lipscombe LL, Levesque L, Gruneir A, Fischer HD, Juurlink DN, Gill SS, et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med. 2009;169:1282-9.
67. Hasnain M, Vieweg WV. Antipsychotic drug-associated acute hyperglycemia in elderly diabetic patients: do the drugs explain the hyperglycemia? Arch Intern Med. 2009;169:2164-5.
68. Gardner DM, Teehan M. Antipsychotics and their side effects. Cambridge: University Press; 2011.
69. Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf. 2009;18:791-9.
70. Cohen D, Correll CU. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. JClin Psychiatry. 2009;70:765-6.
71. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry. 2004;37:1-11.
72. Castilla-Puentes R. Effects of psychotropics on glycosylated hemoglobin (HbA1c) in a cohort of bipolar patients. Bipolar Disord. 2007;9:772-8.
73. Gianfrancesco F, Pesa J, Wang RH, Nasrallah H. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. Am J Health Syst Pharm. 2006;63:431-41.
74. Mattiasson I, Berntorp K, Lindgarde F. Sodium-lithium countertransport and platelet cytosolic free calcium concentration in relation to peripheral insulin sensitivity in postmenopausal women. Clin Sci (Lond). 1992;83:319-24.
75. M uller-Oerlinghausen B, Passoth PM, Poser W, Schlecht W. [Effect of long-term treatment with neuroleptics or lithium salts on carbohydrate metabolism]. Arzneimittelforschung. 1978;28:1522-4.
76. Okosieme OE, Campbell A, Patton K, Evans ML. Transient diabetes associated with withdrawal of lithium therapy. Diabetes Care. 2006;29:1181.
77. Waziri R, Nelson J. Lithium in diabetes mellitus: a paradoxical response. JClin Psychiatry. 1978;39:623-5.
78. Vestergaard P, Schou M. Does long-term lithium treatment induce diabetes mellitus? Neuropsychobiology. 1987;17:130-2.
79. Bilo L, Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecol Endocrinol. 2008;24:562-70.
80. Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011;12:e32-43.
81. Obembe A. Carbamazepine-induced diabetes mellitus. Cent Afr J Med. 1991;37:96-8.
82. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf. 2001;24:969-78.
83. Jerrell JM, McIntyre RS. Metabolic, digestive, and reproductive adverse events associated with antimanic treatment in children and adolescents: a retrospective cohort study. Prim Care Companion J Clin Psychiatry. 2010;12(4).
84. Henneman DH, Altschule MD, Goncz RM. Carbohydrate metabolism in brain disease. II. Glucose metabolism in schizophrenic, manicdepressive, and involutional psychoses. AMA Arch Intern Med. 1954;94:402-16.
85. Kooy F. Hyperglycemia in mental disorders. Brain. 1919;42:214-89.
86. Kretschmer E. Physique and character. London: Kegan, Paul, Trench, Trubner; 1936.
87. Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry. 2003;48:458-61.
88. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3:A42.
89. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord. 2010;12:404-13.
90. Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Scientifi cWorldJournal. 2010;10:321-8.
91. Kemp DE, Ismail-Beigi F, Gao K, Fein EB, Conroy C, Obral S, et a l. Pioglitazone for the treatment of bipolar disorder and co-occuring insulin resistance: preliminary evidence for insulin sensitization as a novel mechanism of antidepressant action. Abstract. New Clinical Drug Evaluation Unit Annual Meeting 2010.
92. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. JDiabetes Complications. 2005;19:113-22.
93. Lustman PJ, GriffiThLS, Freedland KE, Kissel SS, Clouse RE. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;129:613-21.
94. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54:216-26.
95. Davydow DS, Russo JE, Ludman E, Ciechanowski P, Lin EH, Von KorffM, et al. The association of comorbid depression with intensive care unit admission in patients with diabetes: a prospective cohort study. Psychosomatics. 2011;52:117-26.
96. Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care. 2005;28:2668-72.
97. Katon W, Russo J, Lin EH, Heckbert SR, Karter AJ, Williams LH, et a l. Diabetes and poor disease control: is comorbid depression associated with poor medication adherence or lack of treatment intensifi cation? Psychosom Med. 2009;71:965-72.
98. Lin EH, Katon W, Von KorffM, Rutter C, Simon GE, Oliver M, et a l. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;27:2154-60.
99. Williams LH, Rutter CM, Katon WJ, Reiber GE, Ciechanowski P, Heckbert SR, et al. Depression and incident diabetic foot ulcers: a prospective cohort study. Am J Med. 2010;123:748-54.
100. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63:619-30.
101. Sieu N, Katon W, Lin EH, Russo J, Ludman E, Ciechanowski P. Depression and incident diabetic retinopathy: a prospective cohort study. Gen Hosp Psychiatry. 2011;33:429-35.
102. Katon WJ, Lin EH, Williams LH, Ciechanowski P, Heckbert SR, Ludman E, et al. Comorbid depression is associated with an increased risk of dementia diagnosis in patients with diabetes: a prospective cohort study. JGen Intern Med. 2010;25:423-9.
103. Lin EH, Rutter CM, Katon W, Heckbert SR, Ciechanowski P, Oliver MM, et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care. 2010;33:264-9.
104. Lin EH, Heckbert SR, Rutter CM, Katon WJ, Ciechanowski P, Ludman EJ, et al. Depression and increased mortality in diabetes: unexpected causes of death. Ann Fam Med. 2009;7:414-21.
105. Young BA, Von KorffM, Heckbert SR, Ludman EJ, Rutter C, Lin EH, et al. Association of major depression and mortality in Stage 5 diabetic chronic kidney disease. Gen Hosp Psychiatry. 2010;32:119-24.
106. Winkley K, Sallis H, Kariyawasam D, Leelarathna LH, Chalder T, Edmonds ME, et al. Five-year follow-up of a cohort of people with their fi rst diabetic foot ulcer: the persistent effect of depression on mortality. Diabetologia. 2012;55:303-10.
107. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, et a l. Disparities in diabetes care: impact of mental illness. Arch Intern Med. 2005;165:2631-8.
108. Goldberg RW, Kreyenbuhl JA, MedoffDR, Dickerson FB, Wohlheiter K, Fang LJ, et al. Quality of diabetes care among adults with serious mental illness. Psychiatr Serv. 2007;58:536-43.
109. Laursen TM, Munk-Olsen T, Gasse C. Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS One. 2011;6:e24597.
110. Druss BG, von Esenwein SA, Compton MT, Rask KJ, Zhao L, Parker RM. Arandomized trial of medical care management for community mental health settings: the Primary Care Access, Referral, and Evaluation (PCARE) study. Am J Psychiatry. 2010;167:151-9.
111. Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, et a l. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 2007;41:980-9.
112. Hasnain M, Vieweg WV, Fredrickson SK. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. CNS Drugs. 2010;24:193-206.
113. Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapineinduced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71:377-82.
114. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive fi rst-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165:352-8.
115. Ehret M, Goethe J, Lanosa M, Coleman CI. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. JClin Psychiatry. 2010;71:1286-92.
116. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEngl J Med. 2002;346:393-403.
117. Ellinger LK, Ipema HJ, Stachnik JM. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychoticinduced weight gain. Ann Pharmacother. 2010;44:668-79.
118. Barbour KA, Edenfi eld TM, Blumenthal JA. Exercise as a treatment for depression and other psychiatric disorders: a review. JCardiopulm Rehabil Prev. 2007;27:359-67.
119. Ng F, Dodd S, Berk M. The effects of physical activity in the acute treatment of bipolar disorder: a pilot study. JAffect Disord. 2007;101:259-62.
120. Sylvia LG, Ametrano RM, Nierenberg AA. Exercise treatment for bipolar disorder: potential mechanisms of action mediated through increased neurogenesis and decreased allostatic load. Psychother Psychosom. 2010;79:87-96.
121. Kucyi A, Alsuwaidan MT, Liauw SS, McIntyre RS. Aerobic physical exercise as a possible treatment for neurocognitive dysfunction in bipolar disorder. Postgrad Med. 2010;122:107-16.
122. Convit A. Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging. 2005;26 Suppl 1:31-5.
123. Convit A, Wolf OT, Tarshish C, de Leon MJ. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA. 2003;100: 2019-22.
124. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, GoffDC Jr, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. NEngl J Med. 2011;364:818-28.
125. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602-13.
126. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53.
127. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEngl J Med. 2008;358: 2560-72.
128. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191-201.
129. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(3):CD002966.
130. McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. CMAJ. 2005;173:502-4.